FibroBiologics, Inc. entered into a Securities Purchase Agreement on June 25, 2026, for a private placement offering that raised gross proceeds of $3,000,000. The offering included pre-funded warrants to purchase 4,081,633 shares of common stock and warrants to purchase up to 8,163,266 shares at an exercise price of $0.735 per share. Net proceeds to the company were approximately $2.6 million. FibroBiologics, Inc. is a biotechnology company focused on the development and manufacture of biologics.
